In-house vs third-party peptide CoA: what procurement should actually require

Buyers often ask whether a peptide CoA is “third-party tested.” The better question is: what analytical claims are lot-specific, which lab produced them, and can you verify the lot? This guide separates in-house release testing from independent lab summaries without marketing theater.

What an in-house lot CoA should still prove

A serious in-house CoA is still lot-specific: HPLC purity method and result, MS identity, net peptide content, and clear lot linkage to the vial you received.

In-house does not mean useless—it means you must evaluate method transparency, instrument class, and whether chromatograms are available on request.

What independent third-party summaries add

Third-party summaries can reduce conflict-of-interest concerns when the same lot is re-tested outside the releasing lab. They do not replace lot linkage, and a third-party PDF for a different lot is not evidence for yours.

Ask which tests were repeated, which lab performed them, and whether the report number maps to your shipment lot.

What neither document proves

Neither an in-house nor a third-party CoA makes a material suitable for human use. RUO boundaries remain absolute.

Neither document replaces your receiving SOP: match labels, store correctly, and quarantine mismatches.

BluGen practice

Every BluGen order ships with a lot-specific CoA (HPLC, MS identity, net peptide content). Independent third-party summaries are available on lots where that testing is on file—ask procurement for the packet when required by your vendor qualification.

Public lot verification lives in the CoA Library when lots are published.